Mark Thalgott1, Brigitte Rack2, Thomas Horn3, Matthias M Heck3, Matthias Eiber4, Hubert Kübler3, Margitta Retz3, Jürgen E Gschwend3, Ulrich Andergassen2, Roman Nawroth3. 1. Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany mark.thalgott@lrz.tum.de. 2. Department of Gynaecology and Obstetrics, Ludwig Maximilian University, Munich, Germany. 3. Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany. 4. Department of Radiology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
Abstract
AIM: Circulating tumour cells (CTCs) may be prognostic for biochemical recurrence-free survival (bRFS) in patients with locally advanced high-risk prostate cancer (LAPC) undergoing neoadjuvant chemohormonal therapy (NCHT) and radical prostatectomy (RP). PATIENTS AND METHODS: CTCs were detected before and after NCHT, after RP and at follow-up using the CellSearch™-System for 59 blood samples (20 ml) from patients with LAPC (n=15) and, additionally, for 15 control samples. RESULTS: The median 5-year progression risk was 90%. CTCs (≥1/20 ml) were detected in 53.3% of patients, with a detection rate of 18.6% in sample-adjusted analysis. CTCs were detected at baseline in 20% of patients with LAPC and 6.7% of controls (p=0.6). CTC findings displayed no association with clinicopathological characteristics. The median bRFS of CTC-negative vs. CTC-positive patients was 43.7 (95% confidence interval not reached) vs. 29.2 months (95% confidence interval=26.8-60.6 months), without statistical significance (p=0.76). CONCLUSION: During NCHT and RP, longitudinal CTC presence seems to some extent stochastic, although patients with persistant CTCs post-RP developed biochemical recurrence. No significant association with clinicopathological characteristics or bRFS was observed in patients with LAPC, despite a trend for reduced bRFS in patients with detectable CTCs. Copyright
AIM: Circulating tumour cells (CTCs) may be prognostic for biochemical recurrence-free survival (bRFS) in patients with locally advanced high-risk prostate cancer (LAPC) undergoing neoadjuvant chemohormonal therapy (NCHT) and radical prostatectomy (RP). PATIENTS AND METHODS: CTCs were detected before and after NCHT, after RP and at follow-up using the CellSearch™-System for 59 blood samples (20 ml) from patients with LAPC (n=15) and, additionally, for 15 control samples. RESULTS: The median 5-year progression risk was 90%. CTCs (≥1/20 ml) were detected in 53.3% of patients, with a detection rate of 18.6% in sample-adjusted analysis. CTCs were detected at baseline in 20% of patients with LAPC and 6.7% of controls (p=0.6). CTC findings displayed no association with clinicopathological characteristics. The median bRFS of CTC-negative vs. CTC-positive patients was 43.7 (95% confidence interval not reached) vs. 29.2 months (95% confidence interval=26.8-60.6 months), without statistical significance (p=0.76). CONCLUSION: During NCHT and RP, longitudinal CTC presence seems to some extent stochastic, although patients with persistant CTCs post-RP developed biochemical recurrence. No significant association with clinicopathological characteristics or bRFS was observed in patients with LAPC, despite a trend for reduced bRFS in patients with detectable CTCs. Copyright
Authors: Federico La Manna; Sofia Karkampouna; Eugenio Zoni; Marta De Menna; Janine Hensel; George N Thalmann; Marianna Kruithof-de Julio Journal: Cold Spring Harb Perspect Med Date: 2019-03-01 Impact factor: 6.915
Authors: Almudena Zapatero; Antonio Gómez-Caamaño; María Ángeles Cabeza Rodriguez; Laura Muinelo-Romay; Carmen Martin de Vidales; Alicia Abalo; Patricia Calvo Crespo; Luis Leon Mateos; Carlos Olivier; Lorena Vega Vega Piris Journal: Radiat Oncol Date: 2020-06-01 Impact factor: 3.481